Anatomic Stage III Breast Cancer AJCC v8 Clinical Trials in Boston, Massachusetts

6 studies are recruiting for anatomic stage iii breast cancer ajcc v8 in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

   This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   556 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06058377 on ClinicalTrials.gov

2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

   This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) …

   Stage

   Phase 2

   Ages

   Any age

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   482 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564377 on ClinicalTrials.gov

3. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

   This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   6 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05422794 on ClinicalTrials.gov

4. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

   This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or can…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   7 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05372640 on ClinicalTrials.gov

5. Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

   This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein called HER2 and that has spread from where it first started (primary site…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07137416 on ClinicalTrials.gov

6. Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

   This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the gr…

   Stage

   Phase 2

   Ages

   65 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06042569 on ClinicalTrials.gov